SEC Filing Summary: Nile Therapeutics, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Nile Therapeutics, Inc. on October 19, 2007, covering events occurring on October 16, 2007. The registrant is a Delaware corporation headquartered in Berkeley, California. Note: The request metadata referenced "Capricor Therapeutics, Inc.," but the filing text explicitly identifies the registrant as "Nile Therapeutics, Inc."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance data.
Material Changes
The primary material change reported is the appointment of a new director to the Board of Directors.
- Event: Appointment of Pedro Granadillo as a member of the Board of Directors.
- Date: October 16, 2007.
- Reference: Details are contained in the press release attached as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items. The document is limited to the disclosure of the board appointment.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details regarding Mr. Granadillo's background and qualifications.
- Confirm the current composition of the Board of Directors following this appointment.
- Review subsequent filings for any financial updates, as this 8-K contains no financial data.